ICCM

Business Context and Reporting Period

Company: IceCure Medical Ltd. (ICCM)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: IceCure is a commercial-stage medical device company developing cryoablation systems (freezing technology) for treating tumors. Its lead product is the ProSense system. The company is focused on obtaining regulatory approval for breast cancer treatment in the U.S. and developing next-generation systems (XSense and MSense).

Key Financial Metrics (Year Ended Dec 31, 2024)

Revenue Breakdown (2024): Disposables ($1,828k), Systems ($1,363k), Exclusive Distribution/Services ($100k).
Geographic Revenue (2024): United States ($870k), Japan ($481k), India ($413k), China ($41k), Other ($1,456k).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased slightly by 2% ($62k) year-over-year. Disposables revenue grew 22% ($325k), while system sales declined 6% ($89k). Revenue from the exclusive distribution agreement in Japan dropped 64% ($174k).
• Geographic Shifts: Revenue from India surged 279% ($304k), while revenue from China plummeted 91% ($399k) due to distributor performance issues.
• Expense Trends: Sales and marketing expenses increased 42% ($1.86M) primarily due to costs associated with the FDA De Novo classification process and Advisory Panel. R&D expenses decreased 14% ($1.18M) due to reduced development costs for the XSense system.
• Liquidity: Cash and cash equivalents decreased by approximately $3.0M. The company utilized an At-The-Market (ATM) facility to raise $9.2M in net proceeds during 2024.

Guidance, Outlook, and Risks

Regulatory Milestones:

• FDA De Novo: An FDA Advisory Panel voted favorably in November 2024 regarding the ProSense system for early-stage breast cancer. A final FDA decision is expected after Q1 2025.
• Other Approvals: The company is seeking regulatory approval for the XSense system in Israel and China, and the ProSense system in China.

Going Concern Warning: Management has concluded that conditions raise substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, cash reserves ($7.6M) are insufficient to fund operations for the next 12 months. The company plans to raise additional capital through equity offerings or strategic partnerships, but there is no assurance such funding will be available.

Key Risks:

• Geopolitical: Ongoing multi-front war in Israel has led to employee reserve call-ups and potential supply chain disruptions.
• Commercialization: Failure to secure FDA approval for breast cancer or obtain reimbursement codes (CPT) could prevent significant revenue generation.
• Distributor Performance: Key distributors in China (Shanghai Medtronic Zhikang) and Thailand (Terumo) have failed to meet minimum purchase targets, leading to potential contract terminations.

Investor Verification Checklist

• FDA Decision Timeline: Verify the exact date and outcome of the FDA's final decision on the ProSense De Novo request for breast cancer, expected post-Q1 2025.
• Cash Runway: Confirm the current cash balance (as of March 2025, reported as ~$6.0M) and the status of any new financing agreements to address the going concern warning.
• China Distribution: Assess the status of the relationship with Shanghai Medtronic Zhikang and the transition of sales to Beijing Turing following the failure to meet purchase targets.
• Reimbursement Status: Verify progress on obtaining permanent CPT Category I codes for breast cancer cryoablation, which are critical for U.S. commercialization.
• Israel Operations: Monitor the impact of the ongoing conflict on employee availability (reserve duty) and manufacturing supply chains.